Sigma-Aldrich completes purchase of Proligo from Degussa

03 April 2005 20:35  [Source: ICIS news]

LONDON (CNI)--US life sciences group Sigma-Aldrich has completed its acquisition of US-headquartered Proligo from German specialty chemicals company Degussa.

 

Terms of the deal were not disclose. However, a Degussa spokeswoman suggested to CNI at the time of the initial purchase announcement in February that the sale price was expected to be around $50m (Euro39m).

 

David Harvey, Sigma-Aldrich's chairman and chief executive said: “The Proligo Group is another key step in our strategy to provide revolutionary technology tools that fully meet the research needs of scientists in the rapidly growing field of genomics. Proligo provides us with one of only four exclusive licences to a key Massachusetts Institute of Technology patent application that covers the use of RNA in gene silencing, the new frontier in genomics research.”

 

Proligo employs around 300 staff worldwide and had sales of $40m in 2004. It supplies genomics research tools including custom DNA, custom RNA and phosphoramidite raw materials used for DNA and RNA synthesis. The company has sites in Hamburg, Paris, Singapore, Kyoto, Lismore, Australia and Boulder, Colorado.

By: Nigel Davis
+44 20 8652 3214

For the latest chemical news, data and analysis that directly impacts your business sign up for a free trial to ICIS news - the breaking online news service for the global chemical industry.

Get the facts and analysis behind the headlines from our market leading weekly magazine: sign up to a free trial to ICIS Chemical Business.

Printer Friendly